The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.
Hyun Kuk KimUdaya S TantrySidney C SmithMyung Ho JeongSeung-Jung ParkMoo-Hyun KimDo-Sun LimEun-Seok ShinDuk-Woo ParkYong HuoShao-Liang ChenZheng BoShinya GotoTakeshi KimuraSatoshi YasudaWen-Jone ChenMark ChanDaniel AradiTobias GeislerDiana A GorogDirk SibbingGregory Yoke Hong LipDominick J AngiolilloPaul A GurbelYoung-Hoon JeongPublished in: Thrombosis and haemostasis (2020)
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
Keyphrases
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- patient reported outcomes
- metabolic syndrome
- percutaneous coronary intervention
- coronary artery disease
- venous thromboembolism
- oxidative stress
- ischemia reperfusion injury
- cardiovascular events
- brain injury
- blood brain barrier
- cardiovascular risk factors
- binding protein
- quality improvement
- patient reported